Malin (MLLNF) Other Gross PPE : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Malin Other Gross PPE?

Malin's Other Gross PPE for the quarter that ended in Jun. 2024 was $0.00 Mil.

Malin's quarterly Other Gross PPE increased from Jun. 2023 ($0.22 Mil) to Dec. 2023 ($0.98 Mil) but then declined from Dec. 2023 ($0.98 Mil) to Jun. 2024 ($0.00 Mil).

Malin's annual Other Gross PPE increased from Dec. 2021 ($0.57 Mil) to Dec. 2022 ($0.74 Mil) and increased from Dec. 2022 ($0.74 Mil) to Dec. 2023 ($0.98 Mil).

Malin Other Gross PPE Historical Data

The historical data trend for Malin's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Other Gross PPE Chart

Malin Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

6.56

7.54

0.57

0.74

0.98

Malin Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial														-	0.74	0.22	0.98	-

Malin Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Malin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (OTCPK:MLLNF) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

MLC:Ireland 0Y71:UK

Address

50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02

Website

http://www.malinplc.com

Malin Corporation PLC is a global life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where they believe innovative life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines